How much alcohol you drink depends a lot on where you live, USA Today reports.» Read More
Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.
This month, the full moon falls on Friday the 13th. Freaky? Nah, probably not.
Data released shows weaker health care spending in the US.
If the Supreme Court rules in favor of Halliburton and against shareholders, then other businesses will gain, as well.
Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.
Achillion's been a takeover target for years. But Merck's acquisition of Idenix may mean Achillion's time has come.
Baupost Group appears to have made a nearly $1 billion off of Merck's deal to buy Idenix.
A person who found personal information of 413 Obamacare enrollees in an abandoned backpack in Connecticut first contacted a top GOP legislator.
Allergan's board of directors announced on Tuesday that it has unanimously rejected a revised, unsolicited buyout offer from Valeant Pharmaceuticals.
U.S. health officials finalized guidelines for infant formula makers that aim to ensure products meet certain quality controls to keep them safe.
Autism has emerged as the most expensive medical condition to treat in the U.K., as researchers call for more medical research into the condition.
Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.
Dunkin' Donuts CEO says its sandwiches are snacks, not lunch.
Home visits have risen sharply at many private Medicare health plans, which treat close to 16 million elderly and disabled people.
Here are five health care services that Obamacare plans may not cover.
An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.
A Seattle anesthesiologist who allegedly sent sexually explicit texts while he was supervising surgeries has had his medical license suspended.
Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.
A call center worker at Connecticut's health exchange has said he took customers' personal information about of the offices.
Medicare Advantage plans are facing audits that could order them to repay tens of millions of dollars for billing errors.
Get the best of CNBC in your inbox